晚期时间窗取栓中24-48小时梗死体积作为临床结局替代指标的价值可能有限:AURORA协作事后分析
结果显示FIV仅解释5.9%的取栓疗效,FIV与结局关联较弱,相同FIV下取栓组结局优于对照组,提示FIV作为替代结局的价值有限。
要点
- 晚时间窗取栓患者中,24-48小时FIV仅解释5.9%的取栓对90天结局的效应。
- FIV≤100 mL时,相同FIV下取栓组临床结局显著优于最佳药物治疗。
- FIV作为晚时间窗卒中替代结局的效用可能有限。
核心结论
- FIV仅介导取栓对临床结局效应的一小部分,FIV与结局关联较弱,对照组总体结局更差。
- 对于FIV不超过100 mL,取栓相比最佳药物治疗带来显著更好的临床结局。
- FIV作为晚时间窗卒中替代结局的效用可能有限。
研究设计与样本
- AURORA协作的事后分析,基于6项晚时间窗取栓随机试验的患者水平荟萃分析。
- FIV在24-48小时随访CT或MRI上评估,采用多变量二元逻辑回归和中介分析。
主要发现
- 90天结局较差者FIV更大:mRS 1分者中位FIV 13.7 mL(IQR 6.1-31.3),mRS 6分者59.6 mL(18.8-145.0),P<0.01。
- 取栓组中,达到mRS 0-2的估计概率随FIV增加而下降,从0 mL时的65%降至200 mL时的4%。
- 对照组中FIV与mRS 0-2的关联较弱,且mRS 0-2概率总体更低。
- 仅5.9%的取栓对临床结局的效应由FIV减少解释。
关键数值与推荐
- 功能独立定义为90天mRS评分0-2。
- FIV评估时间为24-48小时。
- 取栓组mRS 0-2估计概率:FIV 0 mL时为65%,FIV 200 mL时为4%。
临床怎么用
- 在晚时间窗卒中患者中,不应仅依据24-48小时FIV来推断取栓的临床获益。
- 对于FIV不超过100 mL,取栓仍应作为优于最佳药物治疗的选择。
局限性
- 为事后分析,可能存在选择偏倚和未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The utility of 24- to 48-hour follow-up infarct volume (FIV) as a surrogate outcome in late time-window acute ischemic stroke is unclear. We aimed to determine associations of 24- to 48-hour FIV and clinical outcome in patients presenting >6 hours from last known well with and without endovascular treatment (EVT). METHODS: Post hoc analysis of the AURORA (Thrombectomy for Anterior Circulation Stroke Beyond 6 h From Time Last Known Well) patient-level meta-analysis of 6 randomized trials of late-window EVT. Patients were randomized to EVT or the control arm (best medical care). FIV was assessed on follow-up computed tomography or magnetic resonance imaging at 24 to 48 hours. Multivariable binary logistic regression with adjustment for key covariates was performed to estimate probabilities of achieving functional independence (modified Rankin Scale [mRS] score, 0-2 at 90 days) based on FIV. Mediation analysis was performed to determine the proportion of the EVT effect that is explained by FIV reduction. RESULTS: Four hundred forty-nine patients of 505 patients (88.9%) had available FIV and 90-day mRS and were included. Patients with worse outcomes at 90 days had larger FIV (median FIV in 90-day mRS score, 1:13.7 mL [interquartile range, 6.1-31.3] versus mRS score, 6:59.6 [18.8-145.0]; P<0.01). In the EVT arm, the estimated probability of achieving an mRS score of 0 to 2 declined with increasing FIV, from 65% at 0 mL FIV to 4% at 200 mL. In the control arm, this association was weaker, and the mRS score of 0 to 2 probabilities were overall lower. Only 5.9% of EVT's effect on clinical outcome was explained by FIV reduction. CONCLUSIONS: FIV mediated only a small proportion of the EVT effect on clinical outcome, and the association of FIV and outcomes was much weaker; overall outcomes were worse in the control arm compared with the EVT arm. For FIV up to 100 mL, EVT results in substantially better clinical outcomes than best medical management given the same FIV. The utility of FIV as a surrogate outcome in late time-window stroke may be limited.
引用
- Ospel JM, Brown S, Albers GW, et al. Value of 24- to 48-Hour Infarct Volume as a Surrogate for Clinical Outcome in Late-Window Thrombectomy May Be Limited: A Post Hoc Analysis of the AURORA Collaboration. Stroke. 2025. PMID: 41342132. doi:10.1161/STROKEAHA.125.052109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。